Southern California turns engineering talent into medical hardware.
Los Angeles and San Diego combine device engineering, genomics and a compute-native founder base. We fund the companies where that convergence produces a regulated product, not a demo.
What we fund on the West Coast
Class II and Class III devices with a defined FDA pathway, plus surgical robotics and imaging platforms with reimbursement mapped before scale-up.
Genomics and multi-omics companies whose cost curve, not their biology narrative, is the defensible asset.
AI-native drug discovery teams willing to be measured on translational milestones.
Cross-Pacific advantage
West Coast companies get the shortest route in our network to Indian and Southeast Asian manufacturing, clinical capacity and cost restructuring.
Our Pacific-time coverage overlaps both Asian mornings and US business hours, which is where cross-border rounds actually get executed.
Frequently asked questions
- Do you invest in medical devices in Los Angeles?
- Yes — device and diagnostics companies with regulatory clearance or a defined FDA pathway are a core West Coast focus.
- Is San Diego covered by the Los Angeles desk?
- Yes. The US West desk covers Southern California, the Bay Area and the Pacific Northwest.
- What stage do you enter?
- Series A and Series B, post product-readiness, with US$10 million minimum and reserved follow-on.